young
children
underli
mechan
respons
viral
pathogenesi
fulli
elucid
date
drug
vaccin
employ
improv
clinic
outcom
rsvinfect
patient
paper
report
angiotensinconvert
protect
sever
lung
injuri
induc
rsv
infect
experiment
mous
model
pediatr
patient
moreov
defici
aggrav
rsvassoci
diseas
pathogenesi
mainli
action
angiotensin
ii
type
receptor
furthermor
administr
recombin
protein
allevi
sever
rsvinduc
lung
injuri
find
demonstr
play
critic
role
prevent
rsvinduc
lung
injuri
suggest
promis
potenti
therapeut
target
manag
rsvinduc
lung
diseas
human
respiratori
syncyti
viru
rsv
nonseg
negativesens
singlestrand
rna
viru
belong
paramyxovirida
famili
rsv
common
viru
respons
acut
sever
lower
airway
diseas
infant
young
children
nearli
children
experienc
least
one
rsv
infect
age
year
accord
world
health
organ
approxim
million
new
pediatr
case
rsvassoci
lower
airway
diseas
occur
annual
worldwid
case
occur
develop
countri
mortal
rate
nearli
annual
despit
signific
impact
rsv
infect
infant
morbid
mortal
treatment
option
remain
larg
limit
support
care
current
ribavirin
antivir
drug
approv
treatment
rsvinfect
airway
diseas
although
issu
efficaci
side
effect
restrict
applic
immunocompromis
patient
high
incid
rsv
infect
potenti
caus
sever
respiratori
tract
diseas
vulner
young
children
combin
limit
avail
therapeut
option
highlight
urgent
unmet
global
human
health
need
reninangiotensin
system
ra
play
major
role
maintain
blood
pressur
electrolyt
fluid
homeostasi
homolog
angiotensinconvert
enzym
ace
gene
report
neg
regul
ra
convert
angiotensin
ang
ii
previou
studi
group
other
demonstr
protect
sever
acut
lung
injuri
ali
trigger
sepsi
acid
aspir
sever
acut
respiratori
syndrom
sar
lethal
avian
influenza
viru
moreov
identifi
receptor
sar
coronaviru
also
found
modul
innat
immun
influenc
composit
gut
microbiota
importantli
recombin
protein
proven
effect
improv
lung
patholog
associ
ali
acut
respiratori
distress
syndrom
ard
induc
virus
includ
sar
influenza
current
solubl
version
recombin
test
phase
ii
clinic
trial
patient
ali
mechan
underli
rsvinduc
lung
diseas
associ
longterm
consequ
remain
incomplet
understood
although
lung
inflammatori
respons
like
play
central
role
promot
pathogenesi
rsv
infect
progress
ard
sever
form
ali
contribut
morbid
infant
notabl
recent
studi
show
involv
influenza
lung
injuri
use
recombin
protein
allevi
sever
ali
studi
hypothes
ra
system
mediat
sever
rsvinduc
lung
injuri
find
demonstr
play
import
role
rsvinduc
lung
injuri
administr
recombin
protein
attenu
sever
lung
injuri
preclin
model
rsv
infect
anim
threeweekold
wildtyp
wt
abbrevi
mice
experiment
anim
center
beij
china
threeweekold
knockout
abbrevi
ko
mice
background
hous
anim
facil
beij
institut
microbiolog
epidemiolog
accord
institut
guidelin
experi
involv
human
subject
perform
accord
guidelin
regul
beij
institut
microbiolog
epidemiolog
experiment
protocol
approv
institut
anim
care
use
committe
beij
institut
microbiolog
epidemiolog
id
carri
accord
approv
guidelin
experiment
mous
model
wildtyp
rsv
viru
abbrevi
use
studi
isol
confirm
rsvinfect
patient
beij
children
hospit
genom
sequenc
avail
genbank
databas
access
number
viru
amplifi
cell
freezethaw
infect
cell
harvest
centrifug
g
min
supernat
concentr
centrifug
g
beckman
rotor
concentr
resuspend
pb
viral
suspens
overlaid
onto
discontinu
sucros
gradient
centrifug
g
purifi
viru
band
collect
dilut
pb
concentr
centrifug
rpm
h
purifi
virus
resuspend
pb
store
rsvinduc
lung
injuri
wt
mice
anesthet
l
wv
pentobarbit
sodium
inocul
intranas
pfu
l
pb
mockinfect
mice
bodi
weight
record
daili
viral
infect
progressionfre
surviv
evalu
time
viral
infect
uvinactiv
viral
suspens
mlwell
sixwel
plate
expos
ultraviolet
uv
approxim
inch
uv
light
sourc
min
biosafeti
cabinet
ang
ii
level
measur
describ
elsewher
western
blot
lung
tissu
lyse
ripa
buffer
follow
antibodi
western
blot
use
rat
polyclon
antibodi
rabbit
monoclon
antiac
antibodi
r
system
histolog
examin
follow
anesthet
pentobarbit
sodium
mice
infect
pfu
sacrif
day
day
post
infect
dpi
hematoxylin
eosin
h
e
stain
lung
mous
fix
formalin
embed
paraffin
cut
section
stain
h
e
analyz
patholog
chang
lung
tissu
number
inflammatori
cell
count
data
analyz
statist
present
number
cell
per
field
lung
wettodri
weight
ratio
mice
sacrif
dpi
lung
weigh
dehydr
h
sever
pulmonari
edema
measur
use
lung
wettodri
weight
ratio
viral
titrat
viru
titer
measur
supernat
lung
homogen
mice
dpi
describ
previous
briefli
cell
cultur
monolay
plate
infect
serial
dilut
lung
suspens
overlay
prepar
agar
sigmaaldrich
st
loui
mo
usa
final
concentr
hyclon
laboratori
south
logan
ut
usa
supplement
fetal
calf
serum
gibco
waltham
usa
cell
cultur
day
co
cell
stain
crystal
violet
viral
plaqu
count
viral
titer
calcul
use
reed
muench
method
express
log
pfug
lung
tissu
perform
use
graphpad
prism
softwar
ver
san
diego
ca
usa
valu
p
consid
statist
signific
experi
perform
triplic
least
determin
role
rsvinduc
lung
injuri
first
measur
level
ang
ii
plasma
rsvinfect
patient
total
pediatr
patient
healthi
children
recruit
beij
children
hospit
china
pla
gener
hospit
beij
hospit
clinic
characterist
underli
condit
outcom
individu
describ
tabl
patient
confirm
carri
sole
rsv
viral
genom
fragment
use
pcr
analysi
concomitantli
plasma
level
ang
ii
significantli
elev
rsvinfect
patient
rel
healthi
subject
p
fig
determin
correl
plasma
level
ang
ii
onset
rsv
infect
collect
plasma
sampl
individu
earlyand
latestag
infect
plasma
level
ang
ii
higher
earlystag
day
onset
latestag
day
onset
indic
plasma
level
ang
ii
decreas
rapidli
infect
recoveri
phase
rsv
infect
figur
taken
togeth
data
indic
reninangiotensin
system
play
import
role
host
respons
rsv
infect
evalu
direct
effect
rsv
infect
ra
mice
infect
live
rsv
viru
three
day
viral
infect
plasma
level
ang
ii
measur
rsv
viral
infect
result
signific
increas
ang
ii
level
rel
mock
infect
p
fig
interestingli
rsv
infect
led
greater
increas
ang
ii
level
infect
viru
p
fig
concomitantli
ang
ii
level
lung
homogen
moder
elev
mice
infect
rsv
p
viru
rel
mock
infect
fig
determin
mechan
respons
increas
level
ang
ii
examin
protein
level
convert
ang
ii
ang
accumul
protein
reduc
mice
infect
rsv
viru
rel
mock
infect
fig
importantli
protein
level
dramat
decreas
lung
homogen
mice
infect
rsv
viru
day
postinfect
p
fig
interestingli
level
ace
protein
compar
lung
mice
infect
rsv
mock
viru
fig
data
demonstr
rsv
infect
lead
decreas
express
increas
ang
ii
level
preclin
model
support
critic
role
ra
rsv
infect
investig
impact
live
rsvinduc
clinic
sign
associ
lung
injuri
infect
knockout
ko
wildtyp
wt
mice
rsv
viru
measur
overal
surviv
fourteen
day
post
infect
wt
mice
surviv
wherea
ko
mice
surviv
fig
seven
day
post
rsv
infect
averag
bodi
weight
ko
mice
decreas
rel
wt
mice
p
fig
meanwhil
lung
histopatholog
score
defin
leukocyt
infiltr
cell
count
significantli
reduc
ko
mice
compar
wt
mice
fig
moreov
lung
edema
defin
lung
wettodri
weight
ratio
significantli
greater
rsvinfect
ko
mice
compar
wt
mice
p
fig
indic
sever
lung
injuri
phenotyp
consist
find
viral
titer
lung
tissu
rsvinfect
ko
mice
significantli
higher
approxim
fivefold
rel
rsvinfect
wt
mice
p
fig
furthermor
plasma
level
ang
ii
significantli
elev
ko
mice
compar
wt
mice
p
day
post
infect
fig
similar
find
observ
ko
wt
mice
infect
rsv
viru
independ
experi
wt
mice
aliv
dpi
wherea
ko
mice
surviv
figur
concomitantli
bodi
weight
decreas
ko
mice
compar
wt
mice
dpi
figur
lung
wettodri
weight
ratio
significantli
higher
rsv
ko
mice
rsv
wt
mice
p
figur
viral
titer
rsv
virusinfect
ko
mice
also
significantli
higher
nearli
fivefold
compar
wt
mice
p
figur
collect
result
suggest
play
critic
role
rsvinduc
lung
injuri
thu
interf
express
may
attenu
diseas
sever
follow
respiratori
rsv
infect
protein
effici
protect
rsv
infect
preclin
model
rsv
virusinfect
wt
mice
treat
recombin
protein
mgkg
day
infect
well
dpi
dpi
signific
increas
bodi
weight
observ
n
mice
vehicletr
mice
p
fig
importantli
mice
exhibit
mild
inflammatori
reaction
wherea
sever
histopatholog
damag
includ
fragment
alveolar
wall
infiltr
lymphocyt
observ
vehicletr
mice
concomitantli
leukocyt
cell
count
significantli
decreas
mice
compar
vehicletr
mice
p
fig
moreov
lung
wettodri
weight
ratio
mice
significantli
reduc
p
fig
indic
attenu
lung
edema
mediat
recombin
protein
addit
lung
viral
titer
mice
significantli
decreas
nearli
compar
vehicletr
mice
p
fig
furthermor
plasma
level
ang
ii
significantli
decreas
mice
p
dpi
fig
notabl
mice
infect
rsv
exhibit
mild
patholog
lung
alter
figur
lung
wettodri
weight
ratio
mice
decreas
compar
vehicletr
mice
p
figur
viral
titer
mice
infect
rsv
also
significantli
decreas
compar
vehicletr
mice
p
figur
data
therefor
demonstr
therapeut
effect
recombin
protein
improv
lung
physiolog
histopatholog
vivo
support
potenti
use
protein
allevi
symptom
acut
lung
injuri
rsv
infect
tor
mediat
action
ang
ii
next
assess
efficaci
inhibitor
specif
receptor
examin
vivo
clinic
sign
lung
first
live
rsvinfect
wt
mice
receiv
vehicl
treatment
exhibit
lung
edema
infiltr
inflammatori
cell
fig
inhibitor
losartan
treatment
markedli
attenu
sever
rsvinduc
histopatholog
alter
rsvinfect
mice
fig
next
lung
wettodri
weight
ratio
significantli
reduc
p
inhibitortr
mice
compar
vehicletr
mice
fig
moreov
lung
viral
titer
decreas
markedli
rsv
virusinfect
wt
mice
treat
inhibitor
fig
furthermor
plasma
level
ang
ii
also
reduc
treatment
inhibitor
fig
contrari
inhibitor
signific
effect
lung
wettodri
weight
ratio
figur
viral
titer
figur
suggest
lack
efficaci
inhibitor
rescu
lung
injuri
induc
virusinfect
wt
mice
therefor
data
support
assert
ang
ii
play
critic
role
regul
rsvinduc
ali
preclin
model
previou
demonstr
mediat
rsvinduc
lung
injuri
fig
led
us
hypothes
suppress
attenu
rsvinduc
lung
injuri
ko
mice
test
rsv
virusinfect
ko
mice
treat
mgkg
day
infect
dpi
dpi
dpi
ko
mice
exhibit
mild
inflammatori
chang
wherea
sever
histopatholog
damag
observ
vehicletr
ko
mice
concomitantli
leukocyt
cell
count
reduc
ko
mice
treat
p
fig
lung
wettodri
weight
ratio
decreas
ko
mice
compar
vehicletr
ko
mice
p
fig
moreov
lung
viral
titer
decreas
significantli
ko
mice
compar
vehicletr
ko
mice
fig
note
appar
effect
lung
edema
figur
viral
titer
figur
virusinfect
ko
mice
treat
inhibitor
indic
like
involv
process
rsvinduc
lung
injuri
base
data
propos
may
play
crucial
role
process
rsv
viral
infect
mainli
affect
fig
data
suggest
rsv
infect
caus
sever
lung
injuri
experiment
mous
model
patient
least
part
modul
ra
system
via
downregul
axi
previou
studi
report
use
rsvinduc
lung
injuri
model
test
drug
efficaci
select
reliabl
mous
model
rsv
infect
investig
associ
clinic
abnorm
major
challeng
rsv
research
strain
origin
isol
clinic
sampl
long
standard
laboratori
rsv
strain
use
research
howev
histor
strain
induc
mild
lung
patholog
mice
compar
recent
isol
strain
therefor
attempt
isol
pathogen
virus
clinic
nasopharyng
swab
collect
pediatr
patient
subsequ
identifi
viru
isol
rsv
belong
subgroup
caus
sever
respiratori
diseas
preclin
model
hospitalisol
strain
use
studi
direct
clinic
relev
anticip
strain
wide
use
develop
anim
model
rsv
research
previou
studi
shown
express
lung
patient
pulmonari
diseas
also
healthi
subject
involv
ali
induc
sar
influenza
lethal
importantli
yumiko
imai
et
al
reveal
essenti
receptor
sar
infect
vitro
vivo
protect
individu
develop
sever
acut
lung
failur
moreov
nonspecif
proteas
would
also
interest
investig
role
regul
cellular
metabolit
howev
nonfunct
lung
injuri
process
induc
variou
influenza
viru
subtyp
data
shown
associ
influenza
viru
infect
level
even
differ
influenza
strain
avian
highpath
versu
despit
report
focus
impact
virus
lung
patholog
underli
molecular
mechan
respons
rasand
injuri
fulli
elucid
report
play
import
role
rsvinduc
lung
injuri
associ
increas
plasma
level
ang
ii
rsvinfect
patient
china
nevertheless
consider
larger
cohort
rsvinfect
individu
variou
region
china
requir
confirm
find
live
rsvinduc
lung
injuri
result
signific
downregul
earli
stage
onset
infect
control
function
ra
group
figur
hypothes
rsv
growth
directli
indirectli
relat
rsvinduc
patholog
moreov
studi
provid
molecular
basi
mechan
lung
injuri
patient
infect
rsv
importantli
level
ang
ii
elev
follow
downregul
caus
sever
lung
injuri
via
process
rsv
infect
fig
discoveri
reveal
common
molecular
cellular
mechan
like
share
anim
model
patient
acidaspir
sepsi
sarscov
influenza
viru
rsv
infect
moreov
data
demonstr
defici
aggrav
rsvinduc
ali
administr
solubl
recombin
protein
amelior
lung
injuri
vivo
nevertheless
studi
assess
potenti
therapeut
efficaci
recombin
human
protein
requir
use
differ
anim
model
verifi
protect
effect
rsvinduc
lung
injuri
studi
use
cotton
rat
monkey
studi
rsv
pathogenesi
rsv
vaccin
drug
investig
combin
clinic
find
preclin
studi
reveal
critic
role
ra
pathogenesi
rsvinduc
lung
injuri
demonstr
play
key
role
develop
progress
rsv
infect
collect
find
suggest
intrigu
possibl
target
ra
repres
valuabl
strategi
treat
rsv
infect
modul
repres
potenti
novel
pharmacolog
approach
amelior
rsvinduc
lung
inflamm
mechan
lead
decreas
expressionact
fulli
investig
initi
clinic
studi
found
elev
plasma
concentr
ang
ii
correl
sever
lung
injuri
therefor
hypothes
level
ang
ii
plasma
sampl
patient
rsv
infect
may
reflect
event
lower
respiratori
tract
although
studi
perform
rel
small
cohort
rsvinfect
subject
includ
balanc
represent
spectrum
diseas
caus
pathogen
infanc
importantli
preclin
studi
suggest
infect
caus
viral
respiratori
pathogen
known
caus
lung
diseas
infant
may
also
result
similar
inhibit
express
clinic
studi
requir
clarifi
issu
regard
current
enrol
infant
prospect
studi
test
patient
broad
spectrum
diseas
sever
caus
rsv
base
find
studi
suggest
modul
express
andor
block
lung
injuri
respons
may
repres
potenti
pharmacolog
approach
allevi
rsvinduc
lung
diseas
